Biogen Inc vs HCA Health Inc — how do they compare? Biogen Inc trades at $203.5 (market cap $30.13B), while HCA Health Inc trades at $411 (market cap $89.08B). The key difference: HCA Health Inc is far larger — about 3× Biogen Inc's market cap, and HCA Health Inc pays a 0.76% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | HCA | |
|---|---|---|
Market Cap | $30.13B | $89.08B |
Sector | Health | Health |
52-Week High | $216.63 | $545.13 |
52-Week Low | $128.93 | $361.32 |
Enterprise Value | $37.20B | $139.62B |
Dividend Yield | — | 0.76% |
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →